Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT

Pharmaceutica Acta Helvetiae

Volumn 72, Issue 4, 1997, Pages 209-213

  Queiroz, Regina Helena Costa ^a   Melchior Jr , Enzo ^b   De Souza, Ana Maria ^a   Gouveia, Elias ^c   Barbosa, José Carlos ^d   De Carvalho, Dermeval ^e  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Regl Sanitary Dermatol Outpatient   (Brazil)

^c Clinical Analysis Services   (Brazil)

^d SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^e UNIVERSITY OF RIBEIRÃO PRETO   (Brazil)

Author keywords

Dapsone; Leprosy patient; Multidrug therapy; Side effect

Indexed keywords

CLOFAZIMINE; DAPSONE; RIFAMPICIN;

ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; EOSINOPHILIA; FEMALE; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; INCIDENCE; LEPROSY; MALE; METHEMOGLOBINEMIA; ORAL DRUG ADMINISTRATION; SIDE EFFECT;

CLOFAZIMINE; DAPSONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEPROSTATIC AGENTS; LEPROSY; MALE; METHEMOGLOBINEMIA; RIFAMPIN;

EID: 0011303581     PISSN: 00316865     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-6865(97)00016-2     Document Type: Article

References (17)

1. Banzato, C.E., Magna, L.A., 1991. In vitro effect of dapsone on NADH-methaemoglobin reductase. Int. J. Lepr. Mycobact. Dis. 59, 486-487.
2. Byrd, S.R., Gelber, R.H., 1991. Effect of dapsone on haemoglobin concentration in patients with leprosy. Lepr. Rev. 62, 71-78.
3. Cellona, R.V., Fajardo, T.T. Jr., Kim, D., Hah, Y., Ramassota, T., Sampattavanich, S., Carrilo, M.P., Abalos, R.M., Cruz, B.C., Ito, T., Yuasa, Y., 1990. Joint chemotherapy trials in lepromatous leprosy conducted in Thailand, the Philippines and Korea. Int. J. Lepr. Mycobact. Dis. 58, 1-11.
4. Coleman, M.D., 1993. Dapsone: Modes of action, toxicity and possible strategies for increasing patient tolerance. Br. J. Dermatol. 129, 507-513.
5. Coleman, M.D., 1995. Dapsone toxicity: Some current perspectives. Gen. Pharmacol. 26, 1461-1467.
6. Erstad, B.L., 1992. Dapsone induced methemoglobinemia and hemolytic anemia. Clin. Pharmacol. 11, 800-805.
7. 450: Implications for inhibition of haematoxicity. Br. J. Clin. Pharmacol. 40, 531-538.
8. Katz, S.I.D., 1987. In: Fitzpatrick, K.T.B. et al. (Eds.), Dermatology and General Medicine, 3rd ed. McGraw-Hill, New York, pp. 2570-2574.
9. Kevin Park, B., Coleman, J.W., Kitteringham, N.R., 1987. Drug disposition and drug hypersensitivity. Biochem. Pharmacol. 36, 581-590.
10. Lohr, G.W., Waller, H.D., 1974. Glucose-6-phosphate dehydrogenase. In: Bergmeyer, H.U. (Ed.), Methods of Enzymatic Analysis. Academic Press, New York, p. 636.
11. Mitie Tada, L.R.F., Marzliar, M.C., Pozzani, M., Lafratta, T.E., Nogueira, W., Buzar, M., Oppomolla, D.W., 1993. Preliminary results of the evaluation of a surveillance system of side effects of MDT. Int. J. Lepr. 61 (Suppl.), 4A.
12. Noordeen, S.K., 1995. Eliminating leprosy as a public health problem. Why the optimism is justified. Int. J. Lepr. 63, 559-566.
13. Pertel, P., Hirschtick, R., 1994. Adverse reactions to dapsone in persons infected with human immunodeficiency virus. Clin. Infect. Dis. 18, 630-632.
14. Reeve, P.A., Ala, J., Hall, J.J., 1992. Dapsone syndrome in Vanuatu: A high incidence during multidrug treatment (MDT) of leprosy. J. Trop. Med. Hyg. 95, 266-270.
15. Rhodes, L.E., Tingle, M.D., Park, B.K., Chu, P., Verbov, J.L., Friedmann, P.S., 1995. Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy. Br. J. Dermatol. 132, 257-262.
16. Richardus, J.H., Smith, T.C., 1989. Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy. Lepr. Rev. 60, 267-273.
17. Zuidema, J., Hilbers-Modderman, E.S.M., Merkus, F.W.H.M., 1986. Clinical pharmacokinetics of dapsone. Clin. Pharmacok. 11, 299-315.